Abstract

Objective While albuminuria is a marker for progressive chronic kidney disease (CKD) in patients with type 2 diabetes (T2DM), both albuminuric and normoalbuminuric patients appear prone to vascular injury. This pilot study examines the association between circulating endothelial cell (CEC) levels and vascular injury in patients with T2DM and CKD. Methods In this cross-sectional study, eligible adult patients had T2DM, and stage 3 CKD (estimated glomerular filtration rate between 30 and 60 mL/min/1.73m (2)). CEC levels were tested by Janssen Diagnostics, LLC using an immuno-magnetic bead-based assay. CEC levels were compared to levels in a previously tested normal population. Correlations between CEC levels and other vascular injury markers (urine albumin, von-Willebrand factor antigen, hs-CRP, uric acid) were performed. Results Patients included 40 adults of which nineteen were normoalbuminuric. Mean CEC levels (38.7, SD 38.1 cells) were significantly higher than the normal population (M = 21±18 cells, p<0.001; N = 249), including in the normoalbuminuric subgroup (M = 42.9±42.5 cells, p<0.001). CEC levels were significantly correlated with uric acid levels (r=0.33, p=0.039). Conclusions CEC levels in patients with T2DM and CKD, both albuminuric and normoalbuminuric, are significantly higher than a normal population, suggesting the presence of vascular injury in both groups. Future studies are needed to evaluate the role of CECs as a biomarker to predict outcomes in normoalbuminuric patients with CKD.

Highlights

  • Type 2 diabetes (T2DM) is the most common cause of pre-dialysis chronic kidney disease (CKD) in the United States affecting approximately 10 million Americans[1,2]

  • We found that circulating endothelial cell (CEC) levels are significantly higher than a normal population, and that there was no difference in these levels between normoalbuminuric and albuminuric subgroups

  • CEC levels were significantly correlated with uric acid levels

Read more

Summary

Introduction

Type 2 diabetes (T2DM) is the most common cause of pre-dialysis chronic kidney disease (CKD) in the United States affecting approximately 10 million Americans[1,2]. Of these patients with T2DM and CKD only a small proportion will progress to end stage renal disease (ESRD) requiring dialysis or transplant[2]. Urine microalbumin levels are the most commonly used biomarker for progressive diabetic renal damage[4] They have been found to be a poor predictor of progression to ESRD in T2DM, and are in the normal range in up to 50% of patients with T2DM and CKD5–11. Biomarkers that quantify underlying vascular injury and predict future renal and cardiovascular risk independent of urine microalbumin are needed in this population[7,14]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call